日前，"见未来·2025第八届金禧奖年度评选"结果揭晓，华厦眼科医院集团凭借系统性、引领性、实效 性的品牌创新实践，从众多参选企业中脱颖而出，荣膺"金禧奖·2025创新品牌奖"。 "金禧奖"是由标点财经研究院联合《投资时报》、投资时间网等第三方机构，基于对数千家企业的大数 据分析、比较，再经媒体记者、研究员团队专业评审而产生，以其客观、公正、权威的研究属性，深受 市场认可。 荣获"2025品牌创新奖"，是华厦眼科继入选"中国上市公司品牌价值榜"新锐榜TOP50，获评"国民信赖 十大健康品牌""卓越品牌管理公司""优秀品牌案例"之后，再度斩获的又一重要品牌类殊荣。 "此次获奖，是华厦眼科在品牌建设上持续深耕、从量变到质变的一个标志，助力品牌从'被知晓'到'被 信赖'的价值建设"。华厦眼科医院集团品牌负责人施晶总结道，这一跨越的根本是集团始终恪守"一切 以病人为中心"的理念，致力于让专业的医疗价值、温暖的社会价值与开放的生态价值协同共振，让品 牌成为一份可感知、可分享、可持续的光明承诺。 以创新聚势，筑百年华厦 品牌创新是企业破局生长的"必修课"，亦是抵御市场不确定性的"压舱石"与连接用户的"强纽带"。 作为大型 ...

12月4日，华厦眼科医院集团战略与学术研讨会在厦门盛大召开。中国工程院院士谢立信教授，中华医 学会眼科学分会名誉主委、华厦眼科医院集团战略与学术委员会主委葛坚教授，国际眼科科学院院士、 厦门眼科中心总院长黎晓新教授，国际眼科科学院院士、华厦眼科医院集团专家委员会主席赵堪兴教 授，中华医学会眼科学分会候任主委、华厦眼科医院集团科技创新委员会主席孙兴怀教授，国际眼科科 学院院士、华厦眼科医院集团学科建设委员会主委刘祖国教授，中华医学会眼科学分会副主委杨培增教 授、许迅教授，山东省眼科医院院长史伟云教授，全军眼科专业委员会主委叶剑教授，北京大学人民医 院眼科主任赵明威教授，中山大学中山眼科中心副主任梁凌毅教授，复旦大学附属眼耳鼻喉科医院眼科 研究院副院长赵晨教授，解放军总医院眼科医学部副主任王丽强教授，厦门大学医学院副院长李炜教 授，中华医学会中华眼科杂志黄翊彬教授，福建省医学会眼科学分会常务委员朱益华教授，上海交通大 学附属第一人民医院邵毅教授，华厦眼科医院集团王骞教授、吴国基教授、郭海科教授、王利华教授、 朱思泉教授、张明昌教授、吴护平教授、张广斌教授、潘美华教授、王玉宏教授、黄艳明教授等专家学 者出席会议。 ...

Core Insights - The company reported a steady growth in its semi-annual performance for 2025, achieving an operating income of 2.139 billion yuan, a year-on-year increase of 4.31%, and a net profit attributable to shareholders of 282 million yuan, up 6.20% year-on-year, indicating a recovery in revenue and profit after facing temporary challenges [2] - The company's refractive business emerged as a key highlight, with revenue from this segment growing by 13.75% year-on-year to 789 million yuan, driven by continuous innovation in ophthalmic technology and the introduction of high-end equipment [2][3] Innovation and Technology - Since 2025, the company has focused on technological innovation, particularly in refractive and cataract surgery, by introducing cutting-edge diagnostic and treatment technologies [3] - The company has adopted new refractive surgical techniques, including the Zeiss SMILE Pro and Alcon's full-light plastic surgery, enhancing the efficiency and precision of refractive surgeries [3] - The introduction of the world's first 2MHz femtosecond laser equipment and the SMILE Pro technique has significantly improved surgical outcomes, with the Xiamen Eye Center becoming the first hospital in China to perform over a thousand SMILE Pro surgeries [3] AI and Digital Transformation - The company has deepened the application of advanced technologies such as AI and big data in clinical ophthalmology, enhancing its digital capabilities [4] - Collaborations with institutions like Xiamen University have led to the launch of China's first AI self-test tool for dry eye syndrome, showcasing the company's commitment to innovative solutions [4] - The introduction of the Zeiss EQ Workplace digital system has streamlined the management of cataract surgeries, marking a significant step towards intelligent transformation in the industry [4] Talent Development - The company emphasizes the importance of talent development and team building as a core support for service quality, focusing on a collaborative "medical education and research" system [5] - Partnerships with over 40 universities have been established to promote talent cultivation and clinical research, alongside the recruitment of more than 40 full-time ophthalmic medical professionals and over 200 graduates [5] Future Outlook - The company has a clear development plan for 2025-2029, focusing on internal improvements, optimizing service processes, and expanding its medical service network through new constructions and acquisitions [6] - The company aims to explore overseas ophthalmic market investment opportunities, aligning with its vision of "originating from Xiamen, serving China, and reaching the world" [6]